Thus, we developed CD33 CAR constructs overexpressing LCK, ZAP70, C-JUN, C-Fos, and IFN-γ, and that overexpressing IL-15, a cytokine known to potentiate CAR T therapeutic activity in various tumor models31–33, as a control (Fig. 4A, B and Supplementary Fig. 5A, B). This evidence concerns the gene CD33 and neoplasm.